Intestinal immune regulation as a potential diet-modifiable feature of gut inflammation and autoimmunity

International Reviews of Immunology

Volumn 28, Issue 6, 2009, Pages 414-445

  Scott, Fraser W ^a,b   Sonier, Brigitte ^c   Patrick, Christopher ^c   Ajjikuttira, Prabha ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c NONE

Author keywords

Celiac disease; Dendritic cells; Diet; Gut; Inflammation; Macrophages; Oral tolerance; Regulatory T cells; Type 1 diabetes

Indexed keywords

ANTIGEN; B7 ANTIGEN; CD103 ANTIGEN; CD11B ANTIGEN; CD14 ANTIGEN; CD163 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD86 ANTIGEN; CD8ALPHA ANTIGEN; CHEMOKINE RECEPTOR CCR9; GAMMA INTERFERON; GLYCOPROTEIN GP 96; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT5 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; CELL POPULATION; CELL TYPE; CHRONIC INFLAMMATION; DENDRITIC CELL; DIET; ENTERITIS; GASTROINTESTINAL TRACT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE LYMPHATIC TISSUE; MACROPHAGE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNITY; BACTERIA; DIET; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTESTINAL MUCOSA; INTESTINES;

EID: 71449102303     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830180903208329     Document Type: Review

References (203)

1. A.M. Platt and A.M. Mowat. Mucosal macrophages and the regulation of immune responses in the intestine. Immunol Lett 119: 22-31, 2008.
2. J.L. Coombes and F. Powrie. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8: 435-446, 2008.
3. A. Izcue, J.L. Coombes, and F. Powrie. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 27: 313-338, 2009.
4. T.T. Macdonald and G. Monteleone. Immunity, inflammation, and allergy in the gut. Science 307: 1920-1925, 2005.
5. C. Catassi and A. Fasano. Celiac disease. Curr Opin Gastroenterol 24: 687-691, 2008.
6. M.Mojibian, H. Chakir, D.E. Lefebvre, et al. A diabetes-specific HLA-DR restricted pro-inflammatory T cell response towheat polypeptides in tissue transglutaminase antibody negative patients with type 1 diabetes. Diabetes, 2009.
7. D.E. Lefebvre, K.L. Powell, A. Strom, and F.W. Scott. Dietary proteins as environmental modifiers of type 1 diabetes mellitus. Annu Rev Nutr 26: 175-202, 2006.
8. O. Vaarala, M.A. Atkinson, and J. Neu. The "perfect storm" for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57: 2555-2562, 2008.
9. A. Fasano and T. Shea-Donohue. Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2: 416-422, 2005.
10. M.C. Arrieta, L. Bistritz, and J.B. Meddings. Alterations in intestinal permeability. Gut 55: 1512-1520, 2006.
11. A.M. Mowat. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3: 331-341, 2003.
12. H. Tlaskalova-Hogenova, R. Stepankova, T. Hudcovic, et al. Commensal bacteria (normal microflora), mucosal immunity, and chronic inflammatory and autoimmune diseases. Immunol Lett 93: 97-108, 2004.
13. J. Visser, J. Rozing, A. Sapone, et al. Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 1165: 195-205, 2009.
14. M.G. Laukoetter, P. Nava, and A. Nusrat. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 14: 401-407, 2008.
15. R.D. Newberry and R.G. Lorenz. Organizing a mucosal defense. Immunol Rev 206: 6-21, 2005.
16. M.F. Cesta. Normal structure, function, and histology of mucosa-associated lymphoid tissue. Toxicol Pathol 34: 599-608, 2006.
17. C. Mueller and A.J. Macpherson. Layers of mutualism with commensal bacteria protect us from intestinal inflammation. Gut 55: 276-284, 2006.
18. N.R. Locke, S. Stankovic, D.P. Funda, and L.C. Harrison. TCR gamma delta intraepithelial lymphocytes are required for self-tolerance. J Immunol 176: 6553-6559, 2006.
19. B. Johansson-Lindbom andW.W. Agace. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 215: 226-242, 2007.
20. M. Schenk and C. Mueller. The mucosal immune system at the gastrointestinal barrier. Best Pract Res Clin Gastroenterol 22: 391-409, 2008.
21. D. Kunkel, D. Kirchhoff, S. Nishikawa, et al. Visualization of peptide presentation following oral application of antigen in normal and Peyer's patches-deficient mice. Eur J Immunol 33: 1292-1301, 2003.
22. T.Worbs, U. Bode, S. Yan, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J ExpMed 203: 519-527, 2006.
23. T.W. Spahn, H.L. Weiner, P.D. Rennert, et al. Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. Eur J Immunol 32: 1109-1113, 2002.
24. A.M. Faria and H.L. Weiner. Oral tolerance. Immunol Rev 206: 232-259, 2005.
25. F. Hauet-Broere, W.W. Unger, J. Garssen, et al. Functional CD25- and CD25+ mucosal regulatory T cells are induced in gut-draining lymphoid tissue within 48 h after oral antigen application. Eur J Immunol 33: 2801-2810, 2003.
26. K. Fujihashi, T. Dohi, P.D. Rennert, et al. Peyer's patches are required for oral tolerance to proteins. Proc Natl Acad Sci U S A 98: 3310-3315, 2001.
27. R.L. Jump and A.D. Levine. Murine Peyer's patches favor development of an IL- 10-secreting, regulatory T cell population. J Immunol 168: 6113-6119, 2002.
28. N.M. Tsuji, K. Mizumachi, and J. Kurisaki. Antigen-specific, CD4+CD25+ regulatory T cell clones induced in Peyer's patches. Int Immunol 15: 525-534, 2003.
29. H. Suzuki, S. Sekine, K. Kataoka, et al. Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells. Gastroenterology 135: 917-925, 2008.
30. R.G. Lorenz and R.D. Newberry. Isolated lymphoid follicles can function as sites for induction of mucosal immune responses. Ann N Y Acad Sci 1029: 44-57, 2004.
31. H. Hamada, T. Hiroi, Y. Nishiyama, et al. Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol 168: 57-64, 2002.
32. R.G. Lorenz, D.D. Chaplin, K.G. McDonald, et al. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol 170: 5475-5482, 2003.
33. Y. Kanamori, K. Ishimaru, M. Nanno, et al. Identification of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lymphohemopoietic progenitors develop. J ExpMed 184: 1449-1459, 1996.
34. A. Lugering and T. Kucharzik. Induction of intestinal lymphoid tissue: The role of cryptopatches. Ann N Y Acad Sci 1072: 210-217, 2006.
35. G. Eberl. Inducible lymphoid tissues in the adult gut: Recapitulation of a fetal developmental pathway? Nat Rev Immunol 5: 413-420, 2005.
36. C. Wang, J.S. McDonough, K.G. McDonald, et al. Alpha4beta7/MAdCAM-1 interactions play an essential role in transitioning cryptopatches into isolated lymphoid follicles and a nonessential role in cryptopatch formation. J Immunol 181: 4052-4061, 2008.
37. B. Rocha. The extrathymic T-cell differentiation in the murine gut. Immunol Rev 215: 166-177, 2007.
38. K.S. Michelsen and M. Arditi. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol 14: 48-54, 2007.
39. K. Mahnke, T. Bedke, and A.H. Enk. Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol 250: 1-13, 2007.
40. M. Schenk and C. Mueller. Adaptations of intestinal macrophages to an antigenrich environment. Semin Immunol 19: 84-93, 2007.
41. M. Rescigno, M. Urbano, B. Valzasina, et al. Dendritic cells express tight junction proteins and penetrate gut epithelialmonolayers to sample bacteria. Nat Immunol 2: 361-367, 2001.
42. T. Sminia and S.H. Jeurissen. The macrophage population of the gastro-intestinal tract of the rat. Immunobiology 172: 72-80, 1986.
43. F. Blank, B. Rothen-Rutishauser, and P. Gehr. Dendritic cells and macrophages form a transepithelial network against foreign particulate antigens. Am J Respir Cell Mol Biol 36: 669-677, 2007.
44. T. Spottl, M. Hausmann, M. Kreutz, et al. Monocyte differentiation in intestinelike macrophage phenotype induced by epithelial cells. J Leukoc Biol 70: 241-251, 2001.
45. L.E. Smythies, M. Sellers, R.H. Clements, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75, 2005.
46. G. Rogler, M. Hausmann, D. Vogl, et al. Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol 112: 205-215, 1998.
47. T. Krajina, F. Leithauser, P. Moller, et al. Colonic lamina propria dendritic cells in mice with CD4+ T cell-induced colitis. Eur J Immunol 33: 1073-1083, 2003.
48. P. Smith, N.E. Mangan, C.M. Walsh, et al. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. J Immunol 178: 4557-4566, 2007.
49. T. Hirotani, P.Y. Lee, H. Kuwata, et al. The nuclear IkappaB protein IkappaBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol 174: 3650-3657, 2005.
50. K. Nakata, H. Inagawa, T. Nishizawa, et al. Specific messenger RNA expression for signal transductionmolecules by lipopolysaccharide in intestinalmacrophages. Clin Exp Immunol 143: 484-493, 2006.
51. B.O. Fabriek, M.M. Polfliet, R.P. Vloet, et al. The macrophage CD163 surface glycoprotein is an erythroblast adhesion receptor. Blood 109: 5223-5229, 2007.
52. J.G. Damoiseaux, E.A.Dopp, and C.D. Dijkstra. Cellular binding mechanism on rat macrophages for sialylated glycoconjugates, inhibited by the monoclonal antibody ED3. J Leukoc Biol 49: 434-441, 1991.
53. M.M. Polfliet, B.O. Fabriek, W.P. Daniels, et al. The rat macrophage scavenger receptor CD163: Expression, regulation and role in inflammatory mediator production. Immunobiology 211: 419-425, 2006.
54. C. Buechler, M. Ritter, E. Orso, et al. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol 67: 97-103, 2000.
55. B.O. Fabriek, C.D. Dijkstra, and T.K. Van Den Berg. The macrophage scavenger receptor CD163. Immunobiology 210: 153-160, 2005.
56. D.M. Mosser and J.P. Edwards. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969, 2008.
57. M.M. Tiemessen, A.L. Jagger, H.G. Evans, et al. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A 104: 19446-19451, 2007.
58. P.D. Smith, L.E. Smythies, M. Mosteller-Barnum, et al. Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgAmediated activities. J Immunol 167: 2651-2656, 2001.
59. M. Hausmann, S. Kiessling, S. Mestermann, et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122: 1987-2000, 2002.
60. J. Rugtveit, A. Bakka, and P. Brandtzaeg. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol 110: 104-113, 1997.
61. M. Schenk, A. Bouchon, S. Birrer, et al. Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine. J Immunol 174: 517-524, 2005.
62. A. Bouchon, J. Dietrich, and M. Colonna. Cutting edge: Inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164: 4991-4995, 2000.
63. N. Kamada, T. Hisamatsu, S. Okamoto, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 175: 6900-6908, 2005.
64. T.L. Denning, Y.C. Wang, S.R. Patel, et al. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8: 1086-1094, 2007.
65. N.D. Savage, T. De Boer, K.V. Walburg, et al. Human anti-inflammatory macrophages induce Foxp3+ GITR+ CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J Immunol 181: 2220-2226, 2008.
66. D.H. Munn, E. Shafizadeh, J.T. Attwood, et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J ExpMed 189: 1363-1372, 1999.
67. D.H. Munn and A.L. Mellor. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154, 2007.
68. A.M. Wolf, D. Wolf, H. Rumpold, et al. Overexpression of indoleamine 2,3- dioxygenase in human inflammatory bowel disease. Clin Immunol 113: 47-55, 2004.
69. M.I. Torres, M.A. Lopez-Casado, P. Lorite, and A. Rios. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin Exp Immunol 148: 419-424, 2007.
70. Z. Li and P.K. Srivastava. Tumor rejection antigen gp96/grp94 is an ATPase: Implications for protein folding and antigen presentation. Embo J 12: 3143-3151, 1993.
71. R.J. Binder,D.K.Han, and P.K. Srivastava. CD91: A receptor for heat shock protein gp96. Nat Immunol 1: 151-155, 2000.
72. K. Schreiter, M. Hausmann, T. Spoettl, et al. Glycoprotein (gp) 96 expression: Induced during differentiation of intestinal macrophages but impaired in Crohn's disease. Gut 54: 935-943, 2005.
73. M. Heike, C. Frenzel, D. Meier, and P.R. Galle. Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer. Int J Cancer 86: 489-493, 2000.
74. T. Spoettl, M. Hausmann, M. Herlyn, et al. Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like differentiation of monocytes. Clin Exp Immunol 145: 190-199, 2006.
75. M. Schenk, A. Bouchon, F. Seibold, and C. Mueller. TREM-1-Expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 117: 3097-3106, 2007.
76. J. Rugtveit, E.M.Nilsen, A. Bakka, et al. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112: 1493-1505, 1997.
77. J.P. Hugot, M. Chamaillard, H. Zouali, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603, 2001.
78. Y. Ogura, D.K. Bonen,N. Inohara, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606, 2001.
79. S. Maeda, L.C. Hsu, H. Liu, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 307: 734-738, 2005.
80. M.G. Netea, B.J. Kullberg, D.J. De Jong, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: Implications for Crohn's disease. Eur J Immunol 34: 2052-2059, 2004.
81. A. Iwasaki. Mucosal dendritic cells. Annu Rev Immunol 25: 381-418, 2007.
82. F.G. Chirdo, O.R. Millington, H. Beacock-Sharp, and A.M. Mowat. Immunomodulatory dendritic cells in intestinal lamina propria. Eur J Immunol 35: 1831-1840, 2005.
83. O. Annacker, J.L. Coombes, V. Malmstrom, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 202: 1051-1061, 2005.
84. C.M. Sun, J.A. Hall, R.B. Blank, et al. Small intestine lamina propria dendritic cells promote De novo generation of Foxp3 T reg cells via retinoic acid. J ExpMed 204: 1775-1785, 2007.
85. E. Jaensson, H. Uronen-Hansson, O. Pabst, et al. Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J ExpMed 205: 2139-2149, 2008.
86. B, Johansson-Lindbom, M. Svensson, O. Pabst, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 202: 1063-1073, 2005.
87. M.A. Silva, M. Porras, J. Jury, et al. Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation. Inflamm Bowel Dis 12: 457-470, 2006.
88. I. Monteleone, A.M. Platt, E. Jaensson, et al. IL-10-dependent partial refractoriness to Toll-like receptor stimulation modulates gut mucosal dendritic cell function. Eur J Immunol 38: 1533-1547, 2008.
89. S. Uematsu, M.H. Jang, N. Chevrier, et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol 7: 868-874, 2006.
90. J.L. Coombes, K.R. Siddiqui, C.V. Arancibia-Carcamo, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J ExpMed 204: 1757-1764, 2007.
91. V. Cerovic, C.D. Jenkins, A.G. Barnes, et al. Hyporesponsiveness of intestinal dendritic cells to TLR stimulation is limited to TLR4. J Immunol 182: 2405-2415, 2009.
92. S. Uematsu, K. Fujimoto, M.H. Jang, et al. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol 9: 769-776, 2008.
93. K.R. Siddiqui and F. Powrie. CD103+ GALT DCs promote Foxp3+ regulatory T cells. Mucosal Immunol 1(Suppl 1): S34-S38, 2008.
94. B. Dubois, G. Joubert, M.G. De Aguero, et al. Sequential role of plasmacytoid dendritic cells and regulatory T cells in oral tolerance. Gastroenterology 137: 1019-1028, 2009.
95. M. Iwata. Retinoic acid production by intestinal dendritic cells and its role in T-cell trafficking. Semin Immunol 21: 8-13, 2009.
96. R. Reifen, T. Nur, K. Ghebermeskel, et al. Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-kappaB and collagen formation. J Nutr 132: 2743-2747, 2002.
97. M. Iwata, A. Hirakiyama, Y. Eshima, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21: 527-538, 2004.
98. M. Svensson, B. Johansson-Lindbom, F. Zapata, et al. Retinoic acid receptor signaling levels and antigen dose regulate gut homing receptor expression on CD8+ T cells. Mucosal Immunol 1: 38-48, 2008.
99. D. Mucida, Y. Park, G. Kim, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256-260, 2007.
100. S.G. Kang, H.W. Lim, O.M. Andrisani, et al. Vitamin A metabolites induce guthoming FoxP3+ regulatory T cells. J Immunol 179: 3724-3733, 2007.
101. M.J. Benson, K. Pino-Lagos, M. Rosemblatt, and R.J. Noelle. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J ExpMed 204: 1765-1774, 2007.
102. A. Yokota, H. Takeuchi, N. Maeda, et al. GM-CSF and IL-4 synergistically trigger dendritic cells to acquire retinoic acid-producing capacity. Int Immunol 21: 361-377, 2009.
103. K. Suzuki and S. Fagarasan. How host-bacterial interactions lead to IgA synthesis in the gut. Trends Immunol 29: 523-531, 2008.
104. J. Rey, N. Garin, F. Spertini, and B. Corthesy. Targeting of secretory IgA to Peyer's patch dendritic and T cells after transport by intestinal M cells. J Immunol 172: 3026-3033, 2004.
105. C. Mottet, H.H. Uhlig, and F. Powrie. Cutting edge: Cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 170: 3939-3943, 2003.
106. H. Groux, A. O'Garra, M. Bigler, et al. A CD4+ T-cell subset inhibits antigenspecific T-cell responses and prevents colitis. Nature 389: 737-742, 1997.
107. Q. Tang, K.J. Henriksen,M. Bi, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J ExpMed 199: 1455-1465, 2004.
108. K.V. Tarbell, S. Yamazaki, K. Olson, et al. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J ExpMed 199: 1467-1477, 2004.
109. A.P. Kohm, P.A. Carpentier, H.A. Anger, and S.D. Miller. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immuneresponses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol 169: 4712-4716, 2002.
110. M.E. Morgan, R. Flierman, L.M. Van Duivenvoorde, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 52: 2212-2221, 2005.
111. K.J. Scalapino, Q. Tang, J.A. Bluestone, et al. Suppression of disease in New Zealand Black/New Zealand white lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J Immunol 177: 1451-1459, 2006.
112. J.D. Fontenot, M.A. Gavin, and A.Y. Rudensky. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4: 330-336, 2003.
113. H.H. Uhlig, J. Coombes, C. Mottet, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol 177: 5852-5860, 2006.
114. S. Sakaguchi, M. Ono, R. Setoguchi, et al. Foxp3+CD25+CD4+natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27, 2006.
115. M.G. Roncarolo, S. Gregori, M. Battaglia, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 212: 28-50, 2006.
116. Y. Carrier, J. Yuan, V.K. Kuchroo, and H.L. Weiner. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol 178: 172-178, 2007.
117. S.F. Ziegler. FOXP3: Of mice and men. Annu Rev Immunol 24: 209-226, 2006.
118. D.A. Vignali, L.W. Collison, and C.J. Workman. How regulatory T cells work. Nat Rev Immunol 8: 523-532, 2008.
119. I.I. Ivanov, L. Zhou, and D.R. Littman. Transcriptional regulation of Th17 cell differentiation. Semin Immunol 19: 409-417, 2007.
120. M.A. Curotto De Lafaille and J.J. Lafaille.Natural and adaptive Foxp3+ regulatory T cells: More of the same or a division of labor? Immunity 30: 626-635, 2009.
121. M. Battaglia and M.G. Roncarolo. The fate of human Treg cells. Immunity 30: 763-765, 2009.
122. M. Miyara, Y. Yoshioka, A. Kitoh, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the Foxp3 transcription factor. Immunity 30: 899-911, 2009.
123. H.J. Van der Vliet and E.E. Nieuwenhuis. IPEX as a result of mutations in Foxp3. Clin Dev Immunol 2007: 89017, 2007.
124. M.A. Burchill, J. Yang, C. Vogtenhuber, et al. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178: 280-290, 2007.
125. M.C. Fantini, C. Becker, G. Monteleone, et al. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and downregulation of Smad7. J Immunol 172: 5149-5153, 2004.
126. S.Z. Josefowicz and A. Rudensky. Control of regulatory T cell lineage commitment and maintenance. Immunity 30: 616-625, 2009.
127. D. Mucida, N. Kutchukhidze, A. Erazo, et al. Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 115: 1923-1933, 2005.
128. M.O. Li and R.A. Flavell. Contextual regulation of inflammation: A duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468-476, 2008.
129. H. Herfarth and J. Scholmerich. IL-10 therapy in Crohn's disease: At the crossroads. Treatment of Crohn's disease with the anti-inflammatory cytokine interleukin 10. Gut 50: 146-147, 2002.
130. R.N. Fedorak, A. Gangl, C.O. Elson, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482, 2000. (Pubitemid 32198672)
131. S. Schreiber, R.N. Fedorak, O.H. Nielsen, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119: 1461-1472, 2000. (Pubitemid 32198671)
132. L. Steidler, W. Hans, L. Schotte, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352-1355, 2000.
133. H. Braat, P. Rottiers, D.W. Hommes, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 4: 754-759, 2006.
134. R. Kuhn, J. Lohler, D. Rennick, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75: 263-274, 1993.
135. R.K. Sellon, S. Tonkonogy, M. Schultz, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66: 5224-5231, 1998.
136. A. Roers, L. Siewe, E. Strittmatter, et al. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J Exp Med 200: 1289-1297, 2004.
137. R.T. Gazzinelli, M. Wysocka, S. Hieny, et al. In the absence of endogenous IL- 10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J Immunol 157: 798-805, 1996.
138. P.L. Vieira, J.R. Christensen, S. Minaee, et al. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol 172: 5986-5993, 2004.
139. Y.P. Rubtsov, J.P. Rasmussen, E.Y. Chi, et al. Regulatory T cell-derived interleukin- 10 limits inflammation at environmental interfaces. Immunity 28: 546-558, 2008.
140. A.B. Kulkarni, C.G. Huh, D. Becker, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90: 770-774, 1993.
141. L. Gorelik and R.A. Flavell. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12: 171-181, 2000.
142. M.O. Li, S. Sanjabi, and R.A. Flavell. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471, 2006.
143. J.C. Marie, J.J. Letterio, M. Gavin, and A.Y. Rudensky. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 201: 1061-1067, 2005.
144. M.M. Shull, I. Ormsby, A.B. Kier, et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 359: 693-699, 1992.
145. E.M. Shevach. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645, 2009.
146. Y. Onishi, Z. Fehervari, T. Yamaguchi, and S. Sakaguchi. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 105: 10113-10118, 2008.
147. K.Wing, Y. Onishi, P. Prieto-Martin, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322: 271-275, 2008.
148. S. Read, R. Greenwald, A. Izcue, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 177: 4376-4383, 2006.
149. B. Liang, C. Workman, J. Lee, et al. Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol 180: 5916-5926, 2008.
150. L. Zhou, J.E. Lopes, M.M. Chong, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453: 236-240, 2008.
151. L. Steinman. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 13: 139-145, 2007.
152. K. Ichiyama, H. Yoshida, Y. Wakabayashi, et al. Foxp3 inhibits RORgammatmediated IL-17A mRNA transcription through direct interaction with RORgammat. J Biol Chem283: 17003-17008, 2008.
153. L. Zhou, I.I. Ivanov, R. Spolski, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967-974, 2007.
154. A. Laurence, C.M. Tato, T.S. Davidson, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26: 371-381, 2007.
155. B. Jabri and L.M. Sollid. Mechanisms of disease: Immunopathogenesis of celiac disease. Nat Clin Pract Gastroenterol Hepatol 3: 516-525, 2006.
156. A.M. Mowat. Coeliac disease-A meeting point for genetics, immunology, and protein chemistry. Lancet 361: 1290-1292, 2003.
157. L.M. Sollid. Coeliac disease: Dissecting a complex inflammatory disorder. Nat Rev Immunol 2: 647-655, 2002.
158. M.F. Kagnoff. Celiac disease: Pathogenesis of a model immunogenetic disease. J Clin Invest 117: 41-49, 2007.
159. O. Molberg, S.N. McAdam, R. Korner, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 4: 713-717, 1998.
160. Y. Van De Wal, Y. Kooy, P. Van Veelen, et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 161: 1585-1588, 1998.
161. O. Vaarala. Leaking gut in type 1 diabetes. Curr Opin Gastroenterol 24:701-706, 2008.
162. H.K. Akerblom and M. Knip. Putative environmental factors in Type 1 diabetes. Diabetes Metab Rev 14: 31-67, 1998.
163. D.L. Coleman, J.E. Kuzava, and E.H. Leiter. Effect of diet on incidence of diabetes in nonobese diabetic mice. Diabetes 39: 432-436, 1990.
164. F.W. Scott. Food-induced type 1 diabetes in the BB rat. Diabetes Metab Rev 12: 341-359, 1996.
165. A.J. MacFarlane, K.M. Burghardt, J. Kelly, et al. A type 1 diabetes-related protein from wheat (Triticum aestivum). cDNA clone of a wheat storage globulin, Glb1, linked to islet damage. J Biol Chem278: 54-63, 2003.
166. F. Maurano, G. Mazzarella, D. Luongo, et al. Small intestinal enteropathy in non-obese diabetic mice fed a diet containing wheat. Diabetologia 48: 931-937, 2005.
167. P.E. Beales, R.B. Elliott, S. Flohe, et al. A multi-centre, blinded international trial of the effect of A(1) and A(2) beta-casein variants on diabetes incidence intwo rodent models of spontaneous Type I diabetes. Diabetologia 45: 1240-1246, 2002.
168. W. Karges, D. Hammond-McKibben, R.K. Cheung, et al. Immunological aspects of nutritional diabetes prevention inNODmice: A pilot study for the cow'smilk-based IDDM prevention trial. Diabetes 46: 557-564, 1997.
169. J.P. Mordes, R. Bortell, E.P. Blankenhorn, et al. Rat models of type 1 diabetes: Genetics, environment, and autoimmunity. Ilar J 45: 278-291, 2004.
170. R.H.Wallis, K.Wang, L. Marandi, et al. Type 1 diabetes in the BB rat: A polygenic disease. Diabetes 58: 1007-1017, 2009.
171. M.J. Hessner, X. Wang, L. Meyer, et al. Involvement of eotaxin, eosinophils, and pancreatic predisposition in development of type 1 diabetes mellitus in the Bio- Breeding rat. J Immunol 173: 6993-7002, 2004.
172. P. Courtois, G. Nsimba, H. Jijakli, et al. Gut permeability and intestinal mucins, invertase, and peroxidase in control and diabetes-prone BB rats fed either a protective or a diabetogenic diet. Dig Dis Sci 50: 266-275, 2005.
173. S. Graham, P. Courtois, W.J. Malaisse, et al. Enteropathy precedes type 1 diabetes in the BB rat. Gut 53: 1437-1444, 2004.
174. J.B. Meddings, J. Jarand, S.J. Urbanski, et al. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 276: G951-G957, 1999.
175. T. Watts, I. Berti, A. Sapone, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. Proc Natl Acad Sci U S A 102: 2916-2921, 2005.
176. H. Chakir, D.E. Lefebvre, H. Wang, et al. Wheat protein-induced proinflammatory T helper 1 bias in mesenteric lymph nodes of young diabetes-prone rats. Diabetologia 48: 1576-1584, 2005.
177. F.W. Scott, P. Rowsell, G.S. Wang, et al. Oral exposure to diabetes-promoting food or immunomodulators in neonates alters gut cytokines and diabetes. Diabetes 51: 73-78, 2002.
178. R.A. Caicedo, N. Li, C. Des Robert, et al. Neonatal formula feeding leads to immunological alterations in an animal model of type 1 diabetes. Pediatr Res 63: 303-307, 2008.
179. J. Hoorfar, K. Buschard, and F. Dagnaes-Hansen. Prophylactic nutritional modification of the incidence of diabetes in autoimmune non-obese diabetic (NOD) mice. Br J Nutr 69: 597-607, 1993.
180. S.B. Flohe, H.E. Wasmuth, J.B. Kerad, et al. A wheat-based, diabetes-promoting diet induces a Th1-type cytokine bias in the gut of NOD mice. Cytokine 21: 149-154, 2003.
181. E. Bosi, L.Molteni,M.G. Radaelli, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49: 2824-2827, 2006.
182. M. Westerholm-Ormio, O. Vaarala, P. Pihkala, et al. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52: 2287-2295, 2003.
183. R. Auricchio, F. Paparo, M. Maglio, et al. In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes 53: 1680-1683, 2004.
184. J. Honkanen, S. Skarsvik, M. Knip, and O. Vaarala. Poor in vitro induction of FOXP3 and ICOS in type 1 cytokine environment activated T-cells from children with type 1 diabetes. Diabetes Metab Res Rev 24: 635-641, 2008.
185. T. Vorobjova, O. Uibo, K. Heilman, et al. Increased FOXP3 expression in smallbowel mucosa of children with coeliac disease and type I diabetes mellitus. Scand J Gastroenterol 44: 422-430, 2009.
186. A.G. Ziegler, S. Schmid, D. Huber, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 290: 1721-1728, 2003.
187. M. Fuchtenbusch, A.G. Ziegler, and M. Hummel. Elimination of dietary gluten and development of type 1 diabetes in high risk subjects. Rev Diabet Stud 1: 39-41, 2004.
188. M.R. Pastore, E. Bazzigaluppi, C. Belloni, et al. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab 88: 162-165, 2003.
189. J.M. Norris, K. Barriga, G. Klingensmith, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 290: 1713-1720, 2003.
190. M. Mojibian, H. Chakir, A.J. MacFarlane, et al. Immune reactivity to a glb1 homologue in a highly wheat-sensitive patient with type 1 diabetes and celiac disease. Diabetes Care 29: 1108-1110, 2006.
191. S.J. Turley, J.W. Lee, N. Dutton-Swain, et al. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci U S A 102: 17729-17733, 2005.
192. M. Ejsing-Duun, J. Josephsen, B. Aasted, et al. Dietary gluten reduces the number of intestinal regulatory T cells in mice. Scand J Immunol 67: 553-559, 2008.
193. T.M. Brusko, C.H. Wasserfall, M.J. Clare-Salzler, et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54: 1407-1414, 2005.
194. S. Lindley, C.M. Dayan, A. Bishop, et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99, 2005.
195. A. Kukreja, G. Cost, J.Marker, et al.Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 109: 131-140, 2002.
196. S. Paust and H. Cantor. Regulatory T cells and autoimmune disease. Immunol Rev 204: 195-207, 2005.
197. D. Lundsgaard, T.L. Holm, L. Hornum, and H. Markholst. In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes 54: 1040-1047, 2005.
198. J. Visser, J.L. Hillebrands, M. Walther Boer, et al. Prevention of diabetes by a hydrolysed casein-based diet in diabetes-prone BioBreeding rats does not involve restoration of the defective natural regulatory T cell function. Diabetologia 52: 1445-1447, 2009.
199. K. Luopajarvi, E. Savilahti, S.M. Virtanen, et al. Enhanced levels of cow's milk antibodies in infancy in children who develop type 1 diabetes later in childhood. Pediatr Diabetes 9: 434-441, 2008.
200. J. Lempainen, O. Vaarala, M. Makela, et al. Interplay between PTPN22 C1858T polymorphism and cow's milk formula exposure in type 1 diabetes. J Autoimmun 33: 155-164, 2009.
201. E. Savilahti and K.M. Saarinen. Early infant feeding and type 1 diabetes. Eur J Nutr 48: 243-249, 2009.
202. O. Vaarala. Is it dietary insulin? Ann N Y Acad Sci 1079: 350-359, 2006.
203. M. Makela, O. Vaarala, R. Hermann, et al. Enteral virus infections in early childhood and an enhanced type 1 diabetes-associated antibody response to dietary insulin. J Autoimmun 27: 54-61, 2006.